Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

21.08
+1.065.29%
Post-market: 20.98-0.1000-0.47%18:48 EST
Volume:1.65M
Turnover:34.64M
Market Cap:3.29B
PE:-7.24
High:21.31
Open:20.40
Low:20.36
Close:20.02
52wk High:23.77
52wk Low:10.57
Shares:156.16M
Float Shares:142.00M
Volume Ratio:0.86
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9114
EPS(LYR):-2.5705
ROE:-44.44%
ROA:-27.29%
PB:3.55
PE(LYR):-8.20

Loading ...

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

TIPRANKS
·
Feb 06

Denali Therapeutics Announces Positive Phase 1/2 Data for Tividenofusp Alfa in Hunter Syndrome Ahead of Expected 2026 FDA Decision

Reuters
·
Feb 06

Denali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit

Reuters
·
Feb 06

Denali Therapeutics Hosts Webcast on Enzyme TransportVehicle Programs at 2026 WORLDSymposium

Reuters
·
Feb 02

BRIEF-Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™

Reuters
·
Jan 30

Denali Therapeutics Unveils Phase 1 Study Design for DNL952 in Pompe Disease at WORLDSymposium 2026

Reuters
·
Jan 30

Denali Therapeutics Inc: FDA Decision on Tividenofusp Alfa Bla Expected by April 5, 2026

THOMSON REUTERS
·
Jan 30

Denali Therapeutics Announces Data Presentations on Enzyme Transportvehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type a and Pompe Disease at Upcoming 2026 Worldsymposium™

THOMSON REUTERS
·
Jan 30

Denali Therapeutics Coverage Assumed by UBS at Buy

Dow Jones
·
Jan 08

BRIEF-Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026

Reuters
·
Jan 06

Denali Therapeutics reports $872.9 million cash position ahead of key 2026 milestones

Reuters
·
Jan 06

Denali Therapeutics Inc - FDA Lifts Clinical Hold on Dnl952, Phase 1 Study to Proceed

THOMSON REUTERS
·
Jan 06

Denali Therapeutics Inc - Prepares for FDA Approval and Launch of Tividenofusp Alfa

THOMSON REUTERS
·
Jan 06

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

GlobeNewswire
·
Jan 06

Denali Therapeutics Reports Positive Phase 1/2 Results for Tividenofusp Alfa in Hunter Syndrome

Reuters
·
Dec 30, 2025

Does Denali’s $200M Equity Raise And FDA Talks Change The Bull Case For DNLI?

Simply Wall St.
·
Dec 24, 2025

Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy?

Simply Wall St.
·
Dec 17, 2025

Denali Therapeutics Shares Fall in Premarket on Share Offering Price

Dow Jones
·
Dec 10, 2025

BRIEF-Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 Each

Reuters
·
Dec 10, 2025

Denali Therapeutics Inc - Prices Public Offering of 9,142,857 Shares at $17.50 Each

THOMSON REUTERS
·
Dec 10, 2025